Patents by Inventor Luis A. Dellamary

Luis A. Dellamary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20100015263
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: July 16, 2009
    Publication date: January 21, 2010
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Carl LEBEL, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Andrew M. TRAMMEL, Michael Christopher SCAIFE, Jeffrey P. HARRIS
  • CONTROLLED RELEASE ION CHANNEL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20100015228
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.
    Type: Application
    Filed: July 21, 2009
    Publication date: January 21, 2010
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Carl LEBEL, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Andrew M. TRAMMEL, Michael Christopher SCAIFE, Jeffrey P. HARRIS
  • CONTROLLED RELEASE CORTICOSTEROID COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20100009952
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: May 14, 2009
    Publication date: January 14, 2010
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Michael Christopher SCAIFE, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Carl LEBEL, Andrew M. TRAMMEL, Jeffrey P. Harris
  • CONTROLLED RELEASE AURAL PRESSURE MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20100004225
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: June 17, 2009
    Publication date: January 7, 2010
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Michael Christopher SCAIFE, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Carl LEBEL, Andrew M. TRAMMEL, Jeffrey P. HARRIS
  • CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20090325938
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: June 29, 2009
    Publication date: December 31, 2009
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Benedikt Vollrath, Sergio G. Duron, Carl Lebel, Fabrice PIU, Qiang Ye, Luis A. Dellamary, Andrew M. Trammel, Michael Christopher Scaife, Jeffrey P. Harris
  • CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20090324552
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: June 29, 2009
    Publication date: December 31, 2009
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Carl LEBEL, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Andrew M. TRAMMEL, Michael Christopher SCAIFE, Jeffrey P. HARRIS
  • AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS
    Publication number: 20090306225
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: April 21, 2009
    Publication date: December 10, 2009
    Applicants: Otonomy, Inc., The Regents of the University of California
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Andrew M. TRAMMEL, Sergio G. DURON, Fabrice PIU, Luis A. DELLAMARY, Qiang YE, Carl LEBEL, Michael Christopher SCAIFE, Jeffrey P. HARRIS
  • Stabilized preparations for use in metered dose inhalers
    Patent number: 7628978
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 8, 2009
    Assignee: Novartis Pharma AG
    Inventors: Jeffry G. Weers, Ernest G. Schutt, Luis Dellamary, Thomas E. Tarara, Alexey Kabalnov
  • CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
    Publication number: 20090297533
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: May 26, 2009
    Publication date: December 3, 2009
    Applicants: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay LICHTER, Benedikt VOLLRATH, Sergio G. DURON, Michael Christopher SCAIFE, Fabrice PIU, Qiang YE, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. Harris, Andrew M. TRAMMEL
  • PHOSPHOLIPID-BASED POWDERS FOR DRUG DELIVERY
    Publication number: 20090047358
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Application
    Filed: October 24, 2008
    Publication date: February 19, 2009
    Inventors: Jeffry G. WEERS, Thomas E. Tarara, Luis A. Dellamary, Jean G. Riess, Ernest G. Schutt
  • Phospholipid-based powders for drug delivery
    Patent number: 7442388
    Abstract: Phospholipid based powders for drug delivery applications are disclosed. The powders comprise a polyvalent cation in an amount effective to increase the gel-to-liquid crystal transition temperature of the particle compared to particles without the polyvalent cation. The powders are hollow and porous and are preferably administered via inhalation.
    Type: Grant
    Filed: May 8, 2001
    Date of Patent: October 28, 2008
    Inventors: Jeffry G. Weers, Thomas E. Tarara, Luis A. Dellamary, Jean G. Riess, Ernest G. Schutt
  • Dispersion for pulmonary delivery of a bioactive agent
    Publication number: 20080233194
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.
    Type: Application
    Filed: May 27, 2008
    Publication date: September 25, 2008
    Applicant: Nektar Therapeutics
    Inventors: Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov, Jeffry G. Weers, Ernest G. Schutt
  • Respiratory dispersion for metered dose inhalers
    Publication number: 20080226564
    Abstract: A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.
    Type: Application
    Filed: February 5, 2008
    Publication date: September 18, 2008
    Inventors: Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
  • Dispersion for pulmonary delivery of a bioactive agent
    Patent number: 7393544
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: July 1, 2008
    Assignee: Nektar Therapeutics
    Inventors: Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov, Jeffry G. Weers, Ernest G. Schutt
  • Engineered particles and methods of use
    Patent number: 7306787
    Abstract: Engineered particles are provided may be used for the delivery of a bioactive agent to the respiratory tract of a patient. The particles may be used in the form of dry powders or in the form of stabilized dispersions comprising a nonaqueous continuous phase. In particularly preferred embodiments the particles may be used in conjunction with an inhalation device such as a dry powder inhaler, metered dose inhaler or a nebulizer.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: December 11, 2007
    Assignee: Nektar Therapeutics
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Alexey Kabalnov, Ernest G. Schutt, Luis A. Dellamary
  • DISPERSION FOR PULMONARY DELIVERY OF A BIOACTIVE AGENT
    Publication number: 20070212405
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.
    Type: Application
    Filed: February 14, 2007
    Publication date: September 13, 2007
    Inventors: Luis Dellamary, Thomas Tarara, Alexey Kabalnov, Jeffry Weers, Ernest Schutt
  • Stabilized bioactive preparations and method of use
    Patent number: 7205343
    Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: April 17, 2007
    Inventors: Luis A. Dellamary, Thomas Tarara, Alexey Kabalnov, Jeffry Weers, Ernest Schutt
  • NOVEL METHODS AND COMPOSITION FOR DELIVERING MACROMOLECULES TO OR VIA THE RESPIRATORY TRACT
    Publication number: 20070065369
    Abstract: A composition comprises a lipid-based microstructure with at least one bioactive macromolecule. The composition provides improved bioavailability and is capable of rapidly releasing a bioactive macromolecule. It is believed that the improved bioavailability is due, at least in part, to the reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance.
    Type: Application
    Filed: October 19, 2006
    Publication date: March 22, 2007
    Inventors: Adrian BOT, Luis Dellamary, Dan Smith
  • Methods and compositions for the treatment of ocular disorders
    Publication number: 20060292203
    Abstract: The invention provides methods and compositions for the delivery of lipophilic drugs that are useful for the treatment of various ophthalmological diseases, disorders, and pathologies, including the treatment of age-related macular degeneration, diabetic retinopathy, diabetic macular edema, cancer, and glaucoma.
    Type: Application
    Filed: June 7, 2006
    Publication date: December 28, 2006
    Applicant: TargeGen, Inc.
    Inventors: Luis Dellamary, Arek Tabak, Shiyin Yee
  • Methods and compositions for delivering macromolecules to or via the respiratory tract
    Patent number: 7141236
    Abstract: Methods and compositions for delivering macromolecules to or via the respiratory tract, such that the macromolecules exhibit improved local and/or systemic bioavailability are provided. Such methods utilize lipid-based microstructures formed in combination with at least one bioactive macromolecule, which have a superior ability to rapidly release the bioactive macromolecule(s) thereby resulting in improved local and/or systemic bioavailability of the bioactive macromolecule(s). Such improved bioavailability is believed to be due, in part, to reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: November 28, 2006
    Assignee: Nektar Therapeutics
    Inventors: Adrian I. Bot, Luis A. Dellamary, Dan J. Smith